INVO Bioscience 1-for-20 reverse stock split effective July 28; Nasdaq panel grants continued listing until Sept 29

INVO Fertility, Inc.

Reverse split every 20 shares into 1; effective 12:01 a.m. ET July 28, 2023; trading symbol unchanged (INVO).
Post-split shares outstanding ~842,017; authorized shares reduced to 6,250,000; fractional shares rounded up.
Nasdaq Hearings Panel granted continued listing subject to compliance with $1.00 bid price and $2.5M equity by Sept 29, 2023.
Reverse split intended to regain Nasdaq minimum bid price compliance; no assurance of success.
Company previously non-compliant with bid price and equity requirements; July 6 hearing discussed.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

INVO Fertility, Inc.: Effected a 1-for-20 reverse stock split of common stock, adjusting authorized shares to 6,250,000 (effective 2023-07-28).

Change: charter amendment
Effective: 2023-07-28

Exact text from the filing

On July 26, 2023, INVO Bioscience, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”). The Reverse Stock Split will become effective at 12:01 a.m., Eastern Time, on Friday, July 28, 2023

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-025720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.